Tian Yijun, Liu Qian, He Xuelian, Yuan Xun, Chen Yuan, Chu Qian, Wu Kongming
Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Building 303, 1095 Jiefang Avenue, Wuhan, 430030, People's Republic of China.
Clinical Research Center, Wuhan Medical and Healthcare Center for Women and Children, Wuhan, 430030, People's Republic of China.
J Hematol Oncol. 2016 Feb 27;9:14. doi: 10.1186/s13045-016-0246-5.
Non-small cell lung cancer (NSCLC) causes considerable mortality in the world. Owing to molecular biological progress, treatments in adenocarcinoma have evolved revolutionarily while those in squamous lung cancer remain unsatisfied. Recent studies revealed high-frequency alteration of Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-like factor 2 (Keap1/Nrf2) pathway within squamous lung cancer, attracting researchers to focus on this particular pathway. In NSCLC patients, deregulated Nrf2 signal is recognized as a common feature at both DNA and protein level. Emerging associations between Nrf2 and other pathways have been elucidated. MicroRNA was also implicated in the regulation of Nrf2. Agents activating or antagonizing Nrf2 showed an effect in preclinical researches, reflecting different effects of Nrf2 during tumor initiation and progression. Prognostic evaluation demonstrated a negative impact of Nrf2 signal on NSCLC patients' survival. Considering the importance of Nrf2 signal in NSCLC, further studies are required in the future.
非小细胞肺癌(NSCLC)在全球导致了相当高的死亡率。由于分子生物学的进展,腺癌的治疗方法发生了革命性的演变,而鳞状肺癌的治疗方法仍不尽人意。最近的研究揭示了鳞状肺癌中kelch样ECH相关蛋白1/核因子红细胞2样因子2(Keap1/Nrf2)通路的高频改变,吸引了研究人员关注这一特定通路。在NSCLC患者中,Nrf2信号失调在DNA和蛋白质水平上均被视为一个共同特征。Nrf2与其他通路之间新出现的关联已得到阐明。微小RNA也参与了对Nrf2的调节。激活或拮抗Nrf2的药物在临床前研究中显示出了效果,反映了Nrf2在肿瘤发生和进展过程中的不同作用。预后评估表明Nrf2信号对NSCLC患者的生存有负面影响。鉴于Nrf2信号在NSCLC中的重要性,未来还需要进一步的研究。